{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,15]],"date-time":"2026-05-15T13:43:13Z","timestamp":1778852593327,"version":"3.51.4"},"reference-count":28,"publisher":"Springer Science and Business Media LLC","issue":"12","license":[{"start":{"date-parts":[[2025,10,7]],"date-time":"2025-10-07T00:00:00Z","timestamp":1759795200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2025,10,7]],"date-time":"2025-10-07T00:00:00Z","timestamp":1759795200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"funder":[{"name":"Clinical Research Project in Health Services of Shanghai Municipal Health Commission","award":["20224Y0030"],"award-info":[{"award-number":["20224Y0030"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Int J Clin Oncol"],"published-print":{"date-parts":[[2025,12]]},"DOI":"10.1007\/s10147-025-02888-x","type":"journal-article","created":{"date-parts":[[2025,10,7]],"date-time":"2025-10-07T03:16:47Z","timestamp":1759807007000},"page":"2559-2566","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["FLOT vs DOS neoadjuvant chemotherapy in locally advanced gastric cancer: propensity score analysis"],"prefix":"10.1007","volume":"30","author":[{"given":"Lu-yang","family":"Zhang","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sen","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xuan","family":"Zhao","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hao","family":"Li","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lu","family":"Zang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jun-jun","family":"Ma","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0009-0005-4779-4332","authenticated-orcid":false,"given":"Min-hua","family":"Zheng","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Abe","family":"Fingerhut","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2025,10,7]]},"reference":[{"key":"2888_CR1","doi-asserted-by":"publisher","DOI":"10.3322\/caac.21660","author":"H Sung","year":"2021","unstructured":"Sung H, Ferlay J, Siegel RL et al (2021) Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. https:\/\/doi.org\/10.3322\/caac.21660","journal-title":"CA Cancer J Clin"},{"issue":"1","key":"2888_CR2","doi-asserted-by":"publisher","first-page":"146","DOI":"10.1186\/s12876-021-01734-4","volume":"21","author":"S Zheng","year":"2021","unstructured":"Zheng S, Zhang Z, Ding N et al (2021) Identification of the angiogenesis related genes for predicting prognosis of patients with gastric cancer. BMC Gastroenterol 21(1):146","journal-title":"BMC Gastroenterol"},{"issue":"1","key":"2888_CR3","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1056\/NEJMoa055531","volume":"355","author":"D Cunningham","year":"2006","unstructured":"Cunningham D, Allum WH, Stenning SP et al (2006) Perioperative chemotherapy versus surgery alone for resectable gastroesophageal cancer. N Engl J Med 355(1):11\u201320","journal-title":"N Engl J Med"},{"issue":"1","key":"2888_CR4","doi-asserted-by":"publisher","first-page":"37","DOI":"10.4251\/wjgo.v12.i1.37","volume":"12","author":"XZ Wang","year":"2020","unstructured":"Wang XZ, Zeng ZY, Ye X et al (2020) Interpretation of the development of neoadjuvant therapy for gastric cancer based on the vicissitudes of the NCCN guidelines. World J Gastrointest Oncol 12(1):37\u201353","journal-title":"World J Gastrointest Oncol"},{"issue":"3","key":"2888_CR5","doi-asserted-by":"publisher","first-page":"1428","DOI":"10.1245\/s10434-020-09070-9","volume":"28","author":"Y Yan","year":"2021","unstructured":"Yan Y, Yang A, Lu L et al (2021) Impact of neoadjuvant therapy on minimally invasive surgical outcomes in advanced gastric cancer: an international propensity score-matched study. Ann Surg Oncol 28(3):1428\u20131436","journal-title":"Ann Surg Oncol"},{"issue":"16","key":"2888_CR6","doi-asserted-by":"publisher","first-page":"5731","DOI":"10.1002\/cam4.3224","volume":"9","author":"Q Zhao","year":"2020","unstructured":"Zhao Q, Lian C, Huo Z et al (2020) The efficacy and safety of neoadjuvant chemotherapy on patients with advanced gastric cancer: a multicenter randomized clinical trial. Cancer Med 9(16):5731\u20135745","journal-title":"Cancer Med"},{"issue":"9","key":"2888_CR7","doi-asserted-by":"publisher","first-page":"1237","DOI":"10.1001\/jamaoncol.2017.0515","volume":"3","author":"SE Al-Batran","year":"2017","unstructured":"Al-Batran SE, Homann N, Pauligk C et al (2017) Effect of neoadjuvant chemotherapy followed by surgical resection on survival in patients with limited metastatic gastric or gastroesophageal junction cancer: the AIO-FLOT3 trial. JAMA Oncol 3(9):1237\u20131244","journal-title":"JAMA Oncol"},{"issue":"10184","key":"2888_CR8","doi-asserted-by":"publisher","first-page":"1914","DOI":"10.1016\/S0140-6736(18)33189-1","volume":"393","author":"YK Kang","year":"2019","unstructured":"Kang YK, Cho H (2019) Perioperative FLOT: new standard for gastric cancer? Lancet 393(10184):1914\u20131916","journal-title":"Lancet"},{"issue":"12","key":"2888_CR9","doi-asserted-by":"publisher","first-page":"1697","DOI":"10.1016\/S1470-2045(16)30531-9","volume":"17","author":"SE Al-Batran","year":"2016","unstructured":"Al-Batran SE, Hofheinz RD, Pauligk C et al (2016) Histopathological regression after neoadjuvant docetaxel, oxaliplatin, fluorouracil, and leucovorin versus epirubicin, cisplatin, and fluorouracil or capecitabine in patients with resectable gastric or gastro-oesophageal junction adenocarcinoma (FLOT4-AIO): results from the phase 2 part of a multicentre, open-label, randomised phase 2\/3 trial. Lancet Oncol 17(12):1697\u20131708","journal-title":"Lancet Oncol"},{"issue":"10184","key":"2888_CR10","doi-asserted-by":"publisher","first-page":"1948","DOI":"10.1016\/S0140-6736(18)32557-1","volume":"393","author":"SE Al-Batran","year":"2019","unstructured":"Al-Batran SE, Homann N, Pauligk C et al (2019) Perioperative chemotherapy with fluorouracil plus leucovorin, oxaliplatin, and docetaxel versus fluorouracil or capecitabine plus cisplatin and epirubicin for locally advanced, resectable gastric or gastro-oesophageal junction adenocarcinoma (FLOT4): a randomised, phase 2\/3 trial. Lancet 393(10184):1948\u20131957","journal-title":"Lancet"},{"issue":"1","key":"2888_CR11","doi-asserted-by":"publisher","first-page":"702","DOI":"10.1186\/s12885-018-4615-z","volume":"18","author":"Y Wang","year":"2018","unstructured":"Wang Y, Cheng X, Cui YH et al (2018) Efficacy after preoperative capecitabine and oxaliplatin (XELOX) versus docetaxel, oxaliplatin and S1 (DOS) in patients with locally advanced gastric adenocarcinoma: a propensity score matching analysis. BMC Cancer 18(1):702","journal-title":"BMC Cancer"},{"key":"2888_CR12","doi-asserted-by":"publisher","first-page":"6641","DOI":"10.2147\/CMAR.S258360","volume":"12","author":"X Zhang","year":"2020","unstructured":"Zhang X, Huang H, Wei Z et al (2020) Comparison of docetaxel + oxaliplatin + S-1 vs oxaliplatin + S-1 as neoadjuvant chemotherapy for locally advanced gastric cancer: a propensity score matched analysis. Cancer Manag Res 12:6641\u20136653","journal-title":"Cancer Manag Res"},{"issue":"7","key":"2888_CR13","doi-asserted-by":"publisher","first-page":"1521","DOI":"10.1002\/cncr.11660","volume":"98","author":"K Becker","year":"2003","unstructured":"Becker K, Mueller JD, Schulmacher C et al (2003) Histomorphology and grading of regression in gastric carcinoma treated with neoadjuvant chemotherapy. Cancer 98(7):1521\u20131530","journal-title":"Cancer"},{"issue":"3","key":"2888_CR14","doi-asserted-by":"publisher","first-page":"176","DOI":"10.1016\/S1053-4296(03)00031-6","volume":"13","author":"A Trotti","year":"2003","unstructured":"Trotti A, Colevas AD, Setser A et al (2003) CTCAE v3.0: development of a comprehensive grading system for the adverse effects of cancer treatment. Semin Radiat Oncol 13(3):176\u2013181","journal-title":"Semin Radiat Oncol"},{"issue":"2","key":"2888_CR15","doi-asserted-by":"publisher","first-page":"228","DOI":"10.1016\/j.ejca.2008.10.026","volume":"45","author":"EA Eisenhauer","year":"2009","unstructured":"Eisenhauer EA, Therasse P, Bogaerts J et al (2009) New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). Eur J Cancer 45(2):228\u2013247","journal-title":"Eur J Cancer"},{"key":"2888_CR16","unstructured":"National comprehensive Cancer Network. NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines\u00ae)[EB\/OL].Gastric Cancer. Version 1. 2018. https:\/\/www.google.com\/search?q=https%3A%2F%2Fwww.+nccn.org%2Fprofessionals%2Fphysician_gls%2Fdefault.aspx&rlz=1C1GCEU_enIN1163IN1165&oq=https%3A%2F%2Fwww.+nccn.org%2Fprofessionals%2Fphysician_gls%2Fdefault.aspx&gs_lcrp=EgZjaHJvbWUqBggAEEUYOzIGCAAQRRg7MgYIARBFGDrSAQc3MzNqMGo5qAIAsAIB&sourceid=chrome&ie=UTF-8"},{"key":"2888_CR17","doi-asserted-by":"publisher","first-page":"3009","DOI":"10.2147\/CMAR.S200883","volume":"11","author":"K Wang","year":"2019","unstructured":"Wang K, Ren Y, Ma Z et al (2019) Docetaxel, oxaliplatin, leucovorin, and 5-fluorouracil (FLOT) as preoperative and postoperative chemotherapy compared with surgery followed by chemotherapy for patients with locally advanced gastric cancer: a propensity score-based analysis. Cancer Manag Res 11:3009\u20133020","journal-title":"Cancer Manag Res"},{"issue":"1","key":"2888_CR18","doi-asserted-by":"publisher","first-page":"6093","DOI":"10.1038\/s41467-020-19965-6","volume":"11","author":"BK Sah","year":"2020","unstructured":"Sah BK, Zhang B, Zhang H et al (2020) Neoadjuvant FLOT versus SOX phase II randomized clinical trial for patients with locally advanced gastric cancer. Nat Commun 11(1):6093","journal-title":"Nat Commun"},{"issue":"2","key":"2888_CR19","doi-asserted-by":"publisher","first-page":"366","DOI":"10.1007\/s10120-023-01453-7","volume":"27","author":"Y Kurokawa","year":"2024","unstructured":"Kurokawa Y, Doki Y, Kitabayashi R et al (2024) Short-term outcomes of preoperative chemotherapy with docetaxel, oxaliplatin, and S-1 for gastric cancer with extensive lymph node metastasis (JCOG1704). Gastric Cancer 27(2):366\u2013374","journal-title":"Gastric Cancer"},{"issue":"4","key":"2888_CR20","doi-asserted-by":"publisher","first-page":"518","DOI":"10.1016\/j.ejca.2011.12.017","volume":"48","author":"GM Kim","year":"2012","unstructured":"Kim GM, Jeung HC, Rha SY et al (2012) A randomized phase II trial of S-1-oxaliplatin versus capecitabine-oxaliplatin in advanced gastric cancer. Eur J Cancer 48(4):518\u2013526","journal-title":"Eur J Cancer"},{"issue":"1","key":"2888_CR21","doi-asserted-by":"publisher","first-page":"141","DOI":"10.1093\/annonc\/mdu472","volume":"26","author":"Y Yamada","year":"2015","unstructured":"Yamada Y, Higuchi K, Nishikawa K et al (2015) Phase III study comparing oxaliplatin plus S-1 with cisplatin plus S-1 in chemotherapy-naive patients with advanced gastric cancer. Ann Oncol 26(1):141\u2013148","journal-title":"Ann Oncol"},{"issue":"1","key":"2888_CR22","doi-asserted-by":"publisher","DOI":"10.1136\/esmoopen-2016-000130","volume":"2","author":"H Satake","year":"2017","unstructured":"Satake H, Miki A, Kondo M et al (2017) Phase I study of neoadjuvant chemotherapy with S-1 and oxaliplatin for locally advanced gastric cancer (Neo G-SOX PI). ESMO Open 2(1):e000130","journal-title":"ESMO Open"},{"issue":"5","key":"2888_CR23","doi-asserted-by":"publisher","first-page":"934","DOI":"10.1097\/SLA.0b013e318216f449","volume":"253","author":"K Becker","year":"2011","unstructured":"Becker K, Langer R, Reim D et al (2011) Significance of histopathological tumor regression after neoadjuvant chemotherapy in gastric adenocarcinomas: a summary of 480 cases. Ann Surg 253(5):934\u2013939","journal-title":"Ann Surg"},{"issue":"5","key":"2888_CR24","doi-asserted-by":"publisher","first-page":"784","DOI":"10.1097\/SLA.0b013e3182a66588","volume":"258","author":"CL Donohoe","year":"2013","unstructured":"Donohoe CL, O\u2019Farrell NJ, Grant T et al (2013) Classification of pathologic response to neoadjuvant therapy in esophageal and junctional cancer: assessment of existing measures and proposal of a novel 3-point standard. Ann Surg 258(5):784\u2013792 (discussion 792)","journal-title":"Ann Surg"},{"issue":"1","key":"2888_CR25","doi-asserted-by":"publisher","first-page":"36","DOI":"10.1056\/NEJMoa073149","volume":"358","author":"D Cunningham","year":"2008","unstructured":"Cunningham D, Starling N, Rao S et al (2008) Capecitabine and oxaliplatin for advanced esophagogastric cancer. N Engl J Med 358(1):36\u201346","journal-title":"N Engl J Med"},{"issue":"2","key":"2888_CR26","doi-asserted-by":"publisher","first-page":"250","DOI":"10.1093\/annonc\/mdy540","volume":"30","author":"N Boku","year":"2019","unstructured":"Boku N, Ryu M, Kato K et al (2019) Safety and efficacy of nivolumab in combination with S-1\/capecitabine plus oxaliplatin in patients with previously untreated, unresectable, advanced, or recurrent gastric\/gastroesophageal junction cancer: interim results of a randomized, phase II trial (ATTRACTION-4). Ann Oncol Off J Eur Soc Med Oncol 30(2):250\u2013258","journal-title":"Ann Oncol Off J Eur Soc Med Oncol"},{"issue":"26","key":"2888_CR27","doi-asserted-by":"publisher","first-page":"2903","DOI":"10.1200\/JCO.20.02914","volume":"39","author":"Y Kang","year":"2021","unstructured":"Kang Y, Yook J, Park Y et al (2021) PRODIGY: a phase III study of neoadjuvant docetaxel, oxaliplatin, and S-1 plus surgery and adjuvant S-1 versus surgery and adjuvant S-1 for Resectable advanced gastric cancer. J Clin Oncol Off J Am Soc Clin Oncol 39(26):2903\u20132913","journal-title":"J Clin Oncol Off J Am Soc Clin Oncol"},{"issue":"1","key":"2888_CR28","doi-asserted-by":"publisher","DOI":"10.1186\/s12885-019-5675-4","volume":"19","author":"A Wagner","year":"2019","unstructured":"Wagner A, Grabsch H, Mauer M et al (2019) EORTC-1203-GITCG - the \u201cINNOVATION\u201d-trial: Effect of chemotherapy alone versus chemotherapy plus trastuzumab, versus chemotherapy plus trastuzumab plus pertuzumab, in the perioperative treatment of HER2 positive, gastric and gastroesophageal junction adenocarcinoma on pathologic response rate: a randomized phase II-intergroup trial of the EORTC-Gastrointestinal Tract Cancer Group, Korean Cancer Study Group and Dutch Upper GI-Cancer group. BMC Cancer 19(1):494","journal-title":"BMC Cancer"}],"container-title":["International Journal of Clinical Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10147-025-02888-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s10147-025-02888-x\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10147-025-02888-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,11,24]],"date-time":"2025-11-24T22:02:40Z","timestamp":1764021760000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s10147-025-02888-x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,10,7]]},"references-count":28,"journal-issue":{"issue":"12","published-print":{"date-parts":[[2025,12]]}},"alternative-id":["2888"],"URL":"https:\/\/doi.org\/10.1007\/s10147-025-02888-x","relation":{},"ISSN":["1341-9625","1437-7772"],"issn-type":[{"value":"1341-9625","type":"print"},{"value":"1437-7772","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,10,7]]},"assertion":[{"value":"16 May 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"21 September 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"7 October 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no financial or non-financial conflicts of interest related to this work.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"The research plan and data collection have been reviewed and approved by the Ethics Committee of Ruijin Hospital [(2021)\u4e34\u4f26\u5ba1\u7b2c(65)\u53f7].","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval"}}]}}